For our thirty-sixth episode, we're stepping into the world of cutting-edge science. We're talking about a company that is on the front lines in the fight against humanity's toughest diseases—heart disease, cancer, multiple sclerosis. It’s a business built on decades of research, billions of dollars of investment, and the hope of creating blockbuster drugs that can change the world. We are talking about the Swiss giant... Novartis.

When you hear the name Novartis ($NVS), you probably think of a sprawling Swiss healthcare conglomerate, one of the largest pharmaceutical companies in the world with a hand in everything from prescription drugs to generics. For years, it has been a defensive staple in portfolios, known for its broad diversification and steady dividend.

But the real story is that Novartis has fundamentally changed. Through major strategic moves, including the recent spinoff of its Sandoz generics division, the company has transformed into a "pure-play" innovative medicines company. The new focus is laser-sharp: developing high-margin, patent-protected blockbuster drugs in cutting-edge therapeutic areas like oncology and cardiology. However, by shedding its more stable businesses, Novartis is now entirely dependent on the high-stakes, high-reward game of drug discovery.
We're putting the pipeline under the microscope to determine if this leaner, more focused Novartis is poised for a new era of growth or if it has simply traded stability for a much riskier gamble on innovation.


Created with love by Emil Lazzaroni 
2 new episodes per week, until I can find good companies to hold forever. 

This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content. 

Always consult a professional before investing.